Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2017 ASCO Annual Meeting!


Session: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Type: Oral Abstract Session

Time: Saturday June 3, 1:15 PM to 4:15 PM

Location: E450ab

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

Sub-category:
Small Molecules

Category:
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Meeting:
2017 ASCO Annual Meeting

Abstract No:
LBA2501

Citation:
J Clin Oncol 35, 2017 (suppl; abstr LBA2501)

Author(s): David Michael Hyman, Theodore Willis Laetsch, Shivaani Kummar, Steven G. DuBois, Anna F. Farago, Alberto S. Pappo, George D. Demetri, Wafik S. El-Deiry, Ulrik Niels Lassen, Afshin Dowlati, Marcia S. Brose, Valentina Boni, Brian Turpin, Ramamoorthy Nagasubramanian, Scott Cruickshank, Michael Craig Cox, Nora C. Ku, Douglas S. Hawkins, David S. Hong, Alexander E. Drilon; Memorial Sloan Kettering Cancer Center, New York, NY; University of Texas Southwestern, Dallas, TX; Department of Medicine–Oncology, Palo Alto, CA; Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Massachusetts General Hospital, Boston, MA; St. Jude Children's Research Hospital, Memphis, TN; Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA; Fox Chase Cancer Center, Philadelphia, PA; Rigshospitalet, Copenhagen, Denmark; UH Cleveland Medical Center, Cleveland, OH; Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; START Madrid CIOCC, Hospital HM Universitario Sanchinarro, Madrid, Spain; Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Nemour's Children's Hospital, Orlando, FL; Scott Cruickshank and Associates, Santa Barbara, CA; Loxo Oncology, Inc., San Francisco, CA; Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA; The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract Disclosures

Abstract:

Background: Larotrectinib is the first selective small-molecule pan-TRK inhibitor. TRK fusions appear oncogenic independent of tumor lineage, are widely distributed across cancers, and affect all ages. We present an integrated dataset from 3 studies intended to support regulatory approval. Methods: All NTRK fusion pts with RECIST measurable disease enrolled to the adult (NCT02122913, n=8) and pediatric (NCT02637687, n=12) phase I trials and adult/adolescent phase 2 trial (NCT02576431, n=35) were analyzed. TRK fusion status was determined by local testing prior to enrollment. Pts were dosed predominantly at 100mg BID on a continuous 28-day schedule. Primary objective was investigator-assessed overall response rate (ORR) per RECIST v1.1. Secondary endpoints included duration of response (DOR) and safety. Data were cut on 31-JAN-2017. Results: 55 TRK fusion pts (12 peds, 43 adult, range: 4 mo.-76 yrs) were enrolled (median priors=2). Fusions involved NTRK1 (n=25), NTRK2 (n=1), and NTRK3 (n=29), and 14 unique partners. 13 discrete tumor types were treated: salivary (12), sarcoma (10), infantile fibrosarcoma (7), lung (5), thyroid (5), colon (4), melanoma (4), cholangio (2), GIST (2), and other (4). For the 46 pts evaluated to date, the ORR was 78% (95% CI: 64%–89%) with responses in 12 unique tumor types. Responses are ongoing in 29/33 (88%) pts, excluding 3 peds pts whose DOR was censored at attempted curative resection. A median DOR has not been reached as the majority of responders remain on treatment without progression. The longest responder remains on treatment at 23 mos., 8 pts remain in response at >12 mos., and 16 pts at >6 mos. NTRK solvent front mutations were detected in all 4 pts to develop acquired resistance. The most common TEAEs were fatigue (30%), dizziness (28%), and nausea (28%). 5 (11%) pts required dose reductions. Conclusions: Larotrectinib has demonstrated consistent and durable antitumor activity in TRK fusion cancers, across a wide range of ages and tumor types, and was well-tolerated. Larotrectinib could be the first targeted therapy developed in a tissue type-agnostic manner, and the first developed simultaneously in adults and pediatrics. Clinical trial information: NCT02576431, NCT02122913, NCT02637687

 
Other Abstracts in this Sub-Category:

 

1. A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.

Meeting: 2017 ASCO Annual Meeting Abstract No: 105 First Author: Howard A. Burris
Category: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics - Small Molecules

 

2. Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.

Meeting: 2017 ASCO Annual Meeting Abstract No: 2500 First Author: Martin Henner Voss
Category: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics - Small Molecules

 

3. An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.

Meeting: 2017 ASCO Annual Meeting Abstract No: 2503 First Author: Udai Banerji
Category: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics - Small Molecules

 

More...